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Background: Preventing and managing exacerbations is one major component in COPD treat-
ment. We investigated whether EPs 7630, a herbal drug preparation from the roots of Pelargo-
nium sidoides, could prolong time to acute exacerbation in patients with COPD stage II/III.
Methods: In this randomised, double-blind, placebo-controlled clinical trial, patients were
randomly allocated to oral 24-week add-on therapy with 3  30 drops/day EPs 7630
(n Z 99) or placebo (n Z 101) to a standardised baseline-treatment. Primary endpoint was
time to first exacerbation of COPD. Secondary endpoints were number of exacerbations, con-
sumption of antibiotics, quality of life, patient satisfaction, inability to work, and tolerability.S, acquired immune deficiency syndrome; COPD, chronic obstructive pulmonary disease; EPs 7630, a
s of Pelargonium sidoides; FAS, full analysis set; FEV1, forced expiratory volume during one second;
bal Initiative for Chronic Obstructive Lung Disease; H0, null-hypothesis; IMPSS, Integrative Medicine
ion-to-treat; LOCF, last observation carried forward; MCID, minimal clinically important difference;
t infections; SD, standard deviation; SGRQ, St. George’s Respiratory Questionnaire.
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692 H. Matthys et al.e EPs 7630 is the active ingredientResults: Median time to exacerbation was significantly prolonged with EPs 7630 compared to
placebo (57 versus 43 days, KaplaneMaier-estimate; p Z 0.005, one-sided centre-stratified
log-rank test). The superiority of EPs 7630 was also confirmed in secondary endpoints, e.g.,
fewer exacerbations, less patients with antibiotic use, improved quality of life, higher patient
satisfaction, and less days of inability to work. The incidence of minor gastrointestinal adverse
events was higher in the EPs 7630 group.
Conclusions: The results demonstrate a statistically significant and clinically relevant superior-
ity of add-on therapy with EPs 7630 over placebo and a good long-term tolerability in the treat-
ment of moderate to severe COPD. EPs 7630 prolonged time to exacerbations and reduced
exacerbation frequency and antibiotic use.
Trial Registration No.: ISRCTN01681733.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terisedbyairflow limitation that is not fully reversible, usually
progressive and associated with an abnormal inflammatory
response of the lung to noxious particles or gases.1 A pheno-
type of COPD is chronic bronchitis, which is defined as the
presence of chronic productive cough for at least 3 months/
year in two consecutive years.2 A systematic review showed
that COPDmay affect 9e10% of adults40 years.3 One of the
most common risk factors is cigarette smoking, but there is
consistent evidence from epidemiologic studies4 that non-
smokers may develop chronic airflow obstruction due to
occupational dusts and chemicals,5 passive smoking6 and in-
door and outdoor air pollution.7 Acute COPD exacerbations
contribute to themorbidity andmortality associatedwith the
disease and account for the greatest burden on the health
care system due to frequent clinic visits, hospitalisations and
lost productivity.8 Effective COPD management includes
assessment and monitoring of the disease, reducing risk fac-
tors, managing stable disease and e as a major aim e pre-
vention and management of exacerbations.1,9 Therapeutic
alternatives or add-on therapies to the standardised guideline
treatment which could reduce exacerbations are highly
desired. A promising therapeutic option may be EPs 7630e, a
herbal drug preparation from Pelargonium sidoides roots, for
which anti-infective activities and notable immune-
modulatory capabilities have been demonstrated in vitro,
e.g. moderate direct antibacterial activity,10 strong indirect
antibacterial activity like inhibition of interaction between
group A-streptococci and host epithelia,11 improved phago-
cytosis, improved oxidative burst and intracellular killing by
human peripheral blood phagocytes,12 release of tumour ne-
crosis factorandnitricoxide,13 stimulationof interferone-b,10
increase of natural killer cell activity,14 and inhibition of
sickness behaviour in mice.15 Systematic meta-analysis of
clinical trials with EPs 7630 in acute bronchitis showed supe-
rior efficacy compared to placebo with a significantly more
effective and faster reduction of bronchitis-specific symp-
toms such as coughing, sputum production and dyspnoea, as
well as a good tolerability.16 Encouraging results for the effi-
cacy and safety of Pelargonium sidoides have also been re-
ported in acute rhinosinusitis17,18 and common cold.19of the product Umckaloabo (ISOThe aim of this multicentre, placebo-controlled, double-
blind clinical study was to investigate whether EPs 7630
prolongs time to first exacerbation and reduces exacerba-
tion frequency compared to placebo as an add-on therapy
in patients with moderate to severe COPD.Methods
Study subjects
Patients eligible to participate in the study were male or
female adults (18 years) with a history of chronic bron-
chitis (characterised by cough and sputum production on
most days for 3 months/year for at least 2 consecutive
years), stable disease, 3 exacerbations in the prior 12
months and a forced expiratory volume during one second
(FEV1; post-bronchodilator spirometric measurement) <80%
and 30% of predicted normal value (COPD-II/III). The
spirometry for grading and reversibility testing of the COPD
patients was always performed at least 6 h after the last
ipratropiumbromide/fenoterol inhalation. Only patients
with an improvement of FEV1 0.3 l after 2 puffs of ipra-
tropiumbromide/fenoterol, who had given written
informed consent, were included in the study. Major
exclusion criteria were: relevant cardiac diseases, pneu-
monia, active pulmonary tuberculosis, cystic fibrosis,
bronchiectasis, lung cancer, asthma, infiltrates or other
abnormalities of the lungs, COPD-IV, acute exacerbation
within the last 4 weeks, known concomitant bacterial
infection or respiratory tract infections (RTI), AIDS;
concomitant medication with beta-blockers, ACE-in-
hibitors, regular inhalative glucocorticoids (except COPD-
III) or oral glucocorticosteroids (except during an exacer-
bation), anticholinergics (except ipratropiumbromide in
BerodualN), or b-2-agonists other than salmeterol or
fenoterol in BerodualN, analgesics except paracetamol,
mucolytics and antitussives other than dextrometorphan/
bromhexine/ammonium chloride (Zedex), immune-
modulators (e.g., bacterial vaccines), or coumarin-
derivatives; known alcohol or drug abuse; tendency to
bleed, gastrointestinal disorders, severe heart, renal or
liver diseases and/or immunosuppression; knownArzneimittel, Ettlingen, Germany).
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lactation; simultaneous participation in another clinical
trial.
Study design
This randomised, double-blind, placebo-controlled clinical
trial with two parallel treatment groups was conducted in
Ukraine in 18 centres situated in the regions of Kiev and
Lugansk between March 2006 and June 2008. The study was
performed according to Good Clinical Practice, the Decla-
ration of Helsinki and legal regulations. Ethics committee
and regulatory authority approvals were obtained before
study commencement.
Interventions
The study comprised patient screening prior to enrolment
and a 24-week double-blind treatment period including
seven regular visits (day 0, weeks 4, 8, 12, 16, 20 and 24 with
a window of 5 days) and intermediary visits in case of an
exacerbation. After obtaining written informed consent,
baseline assessments (demographic data, physical exami-
nations, laboratory tests, chest X-ray, bronchitis symptom
score of cough, sputum and sternal pain, and spirometry
tests to determine FEV1 and FVC before and after ipra-
tropiumbromide/fenoterol) were performed. Ipratropium-
bromide/fenoterol had to be used as a substitute for
salbutamol in bronchoreversibility tests, because the latter
was not available in theUkraine at the time of study conduct.
Eligible patients were then assigned randomly to EPs 7630 or
placebo in a double-blind manner. Randomisation was car-
ried out in balanced blocks using the validated random
number generator RCODE in the biometrical department of
Schwabe Pharmaceuticals by a person not involved in the
clinical conduct of the study. Study medication was
numbered according to a randomisation list and patients
received the medication labelled with their medication
number in the order of inclusion into the study by a phar-
macist. The assigned study medication was dispensed pro-
spectively at enrolment to enable self-initiation of therapy
by the patient. The investigators received sealed emergency
envelopes for individual patients, all of which were returned
unopened after completion of the trial.
According to GOLD,1 inhalative baseline-treatment for
COPD-II included salmeterol (Serevent) regularly and
ipratropiumbromide/fenoterol (BerodualN) as needed and
for COPD-III salmeterol and budesonide (Budesonid)
regularly and BerodualN as needed. In case of exacerba-
tions additional oral prednisolone (Prednisolon) and aug-
mentin (Augmentan) or ofloxacin (Ofloxacin) were
prescribed by the investigator.
As add-on therapy, patients were randomly given either
active trial medication containing EPs 7630, a herbal drug
preparation from the roots of Pelargonium sidoides (1:8e10),
extraction solvent: ethanol 11% (w/w), or matched placebo.
Dosing of the studymedicationwas 3 30 drops/d EPs 7630 or
placebo for 24 weeks. Compliance was documented by
measuring the returned trial medication using a measuring
template. The patients were asked to document chronic
bronchitis symptoms, health status, and consumption ofallowed concomitant and study medication in a diary on a
daily basis during the whole study period. FVC and FEV1 were
measured20 at each visit using a MicroDL spirometer (Micro
Medical Ltd., Rochester, England). Predicted FEV1 values
were calculated21 with reference equations. Spirometry pre-
and post-bronchodilator (two puffs of ipratropiumbromide/
fenoterol) was performed (at least three acceptable ma-
noeuvres, the highest value being documented).
Sample size calculation
Due to the lack of empirical data in the indication under
investigation, there was some uncertainty concerning the
treatment effect and the overall time course to be ex-
pected for the primary outcome variable “time to first
acute exacerbation”. Consequently, the assumptions to be
made for sample size calculation were debatable and it was
doubtful whether the desired power could actually be
achieved in a fixed sample size design. Therefore, the study
was planned and performed with an adaptive interim
analysis.22 For sample size calculation the following as-
sumptions were stated a priori: If the rate of first exacer-
bation of COPD is 0.25 in the active treatment group and
0.50 in the placebo group, the power for early rejection of
H0 in the interim analysis at a1Z 0.0115 with the one-sided
log-rank test is 90% for nZ 204 patients. Thus a sample size
of 2  100 patients should provide sufficient power to
already achieve the study aim in the first stage of the trial if
the assumptions specified above are correct.
Outcomes
The primary efficacy variable was time to first exacerbation
of COPD. Since it is estimated that only 50% of all exacerba-
tions are reported to physicians23 and since there is no
standardised and unanimously accepted definition of exac-
erbation of COPD,24 time of first exacerbation was derived
either from reported or unreported exacerbation. Reported
exacerbations were defined as a COPD deterioration due to a
subjective increase in one or more chronic symptoms over
baseline, e.g. increased sputum production, sputum puru-
lence and/or dyspnoea, which requires an extra visit to the
investigator and may warrant a change in regular therapy,
e.g. treatment with systemic steroids and/or antibiotics
(date of extra-visit, documented by the investigator in the
case record form; i.e. moderate exacerbation). Unreported
exacerbations were derived from the patient’s diary and
defined as an increased use of at least twofold mean dose of
ipratropiumbromide/fenoterol on at least five consecutive
days caused by an increase in respiratory symptoms over
baseline that required change in therapy, but which could be
self-managed by the patient23 (date of first increase, docu-
mented by the patient in the diary; i.e. mild exacerbation).
This definition of exacerbations also complies with the pro-
posed definition that an exacerbation of COPD would be an
increase in respiratory symptoms over baseline that usually
requires change in therapy.24 An acute exacerbation (mod-
erate ormild) was considered as subsided if the total score of
the symptoms cough, sputum production, and sternal pain
documented by the patient in his patient’s diary decreased
to baseline (defined as the mean of total score of these
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five days prior to onset of the current acute exacerbation). In
some patients, an exacerbation was not associated with an
increase in the total scorementioned above. In this case, the
episode was considered as subsided when the mean dose of
ipratropiumbromide/fenoterol on five consecutive days
during the exacerbation was equal or less the mean dose of
the five days prior to the exacerbation.
Secondary efficacy variables were: Number and duration
of exacerbations during treatment, health status (validated,
disease-specific St. George’s Respiratory Questionnaire
(SGRQ)25), patient satisfaction with treatment (Integrative
Medicine Patient Satisfaction Scale (IMPSS), a 5-point verbal
rating scale: 1 Z “very satisfied”, 2 Z “satisfied”,
3 Z “neutral”, 4 Z “dissatisfied”, 5 Z “very dissatisfied”)
and duration of inability to work. Safety parameters
comprised surveillance of adverse events (AEs), laboratory
safety parameters, and sputum examination.
Analysis
Each patient’s allocation to the different analysis pop-
ulations (full analysis set (FAS) according to the intention-
to-treat (ITT) principle, per protocol (PP) set, safety anal-
ysis set) was defined prior to unblinding. The following type
I error rates and decision boundaries for the interim anal-
ysis were specified: Global one-sided type I error rate
a Z 0.025; boundary for the one-sided p-value for
accepting the null-hypothesis within the interim analysis
a0Z 0.40; one-sided local type I error rate for rejecting the
null-hypothesis within the interim analysis a1 Z 0.0115.
The trial could be continued if the p-value of the interim
analysis fell between 0.0115 and 0.40. In this case, the
boundary for rejection of the null-hypothesis after the
second part for the product of p-values of both stages was
ca Z 0.0038.
26 Within the pre-specified confirmatory anal-
ysis the null-hypothesis of equal survival curves was tested
with the one-sided centre-stratified log-rank test. If a pa-
tient did not suffer an exacerbation during follow-up or was
previously lost to follow-up, data were treated as censored.
The corresponding two-sided confidence interval was
calculated. The KaplaneMeier method22 was used to esti-
mate the survival functions, i.e. the probability of suffering
no exacerbation until a certain day during the study period.
Regarding the secondary efficacy variables, descriptive
statistical methods were used for the comparison of both
treatment groups and the resulting p-values were inter-
preted accordingly. After baseline, missing values for effi-
cacy variables were replaced applying the last observation
carried forward (LOCF) method unless stated otherwise.
Results
Study population
The patients were recruited from March through June 2006.
Of the 211 patients enrolled for screening, 200 were subse-
quently randomised and allocated to receive either EPs 7630
(99 patients) or matching placebo (101 patients). Eleven
patients did not fulfil the inclusion and/or exclusion criteria,
6 out of them due to asthma. One patient in the EPs 7630group couldnot beanalysed for efficacydue toearly drop-out
(lost to follow-up at baseline). Thus, the ITT population
comprised 199 patients (EPs 7630: 98; placebo: 101) (Fig. 1).
All patients were included in the safety analysis. The evalu-
ation of demographic data and other baseline characteristics
revealed no noticeable differences between both treatment
groups (Table 1). All patients had been treated previously
with coughandcoldpreparations, antibacterials for systemic
use (EPs 7630: 94.9%; placebo: 98.0%), drugs for obstructive
airwaydiseases (EPs 7630: 94.9%; placebo: 95.1%), analgesics
(EPs 7630: 60.2%; placebo: 57.4%) and nasal preparations
(EPs 7630: 49.0%; placebo: 56.4%) being the most frequently
documented pre-study medication. The most frequently
documented intake of concomitant medication for COPD
according toGOLDwas also comparablebetweenboth groups
(data not shown). Themean duration of treatmentwas about
168 days (planned treatment duration 168 days) and
compliance was nearly 100% in both groups.
Primary efficacy variable
The median time to first exacerbation was 57 days in the
EPs 7630 and 43 days in the placebo group (KaplaneMaier
estimate; mild and moderate exacerbations). The proba-
bility of remaining free of exacerbations was significantly
higher for the EPs 7630 group during the whole study
period, i.e. fewer patients suffered from exacerbations
compared to placebo and the time to first exacerbation was
prolonged (p Z 0.005, one-sided centre-stratified log-rank
test) (Fig. 2a). Confirmatory analysis revealed a statistically
significant advantage of EPs 7630 and therefore the null-
hypothesis of equal survival curves could be rejected
within the interim analysis which is therefore identical with
the final analysis presented in this publication. There was
also a statistically significant advantage of EPs 7630 with
respect to moderate exacerbations which was even more
pronounced (p < 0.0001), whereas the difference for mild
exacerbations was not significantly different between both
groups (p Z 0.0949) (Fig. 2b and c). Similar survival curves
with a significant difference between the two treatment
groups were also revealed by subgroup analysis of moderate
exacerbations in COPD II patients, smokers, ex-smokers and
never-smokers, males and females. These data, together
with the corresponding FEV1 value at baseline and the
consumption of ipratropiumbromide/fenoterol during the
study, are shown in Table 2.
Secondary efficacy variables
The mean number  SD of moderate and mild exacerbations
(moderate only/mild only) during treatment was 1.80 1.64
(0.38  0.53/1.69  1.66) with EPs 7630 compared to
2.20 1.59 (0.86 0.68/1.94 1.67) with placebo (pZ 0.08
(p < 0.001/p Z 0.298), two-sided t-test). For EPs 7630 pa-
tients, the median duration of moderate exacerbations was
about one day shorter (11 versus 12 days; p Z 0.102, two-
sided t-test). In the EPs 7630 group, 37/98 (37.8%) patients
needed antibiotic treatment with augmentin or ofloxacin
during exacerbations compared to 74/101 (73.3%) of placebo
patients (p< 0.0001, two-sidedc2-test), with a shortermean
duration of treatment (8 versus 9.8 days, pZ 0.0466, two-
Figure 1 Flow diagram: disposition of patients and analysis sets.
Efficacy of EPs 7630 in COPD 695sided t-test). Themean decrease frombaseline toweek 24 in
the total SGRQ score was 12.7  10.7 for EPs 7630 and
7.0  11.5 points for placebo, respectively (p < 0.01, two-
sided t-test) (Fig. 3). After 24 weeks, patient satisfaction
with treatment was significantly higher with EPs 7630
compared to placebo (p < 0.0001, two-sided Man-
teleHaenszel c2-test) (Fig. 4). The mean number of days off
work during an exacerbation (mild and moderate) was
1.97  3.2 with EPs 7630 and 4.08  6.1 with placebo
(pZ 0.004, two-sided t-test), and the total number within
the 24-week study periodwas 2.96 4.7 and 7.17 8.1 days,
respectively (p < 0.001, two-sided t-test) (Fig. 5).
Safety analysis
During the treatment period, 51/99 (51.5%) patients
treated with EPs 7630 suffered from 79 adverse events
(AEs) compared to 40/100 (40.0%) patients with 46 AEs in
the placebo group, most of which were mild in intensity.None of the AEs were classified as serious. A causal rela-
tionship of AEs with the study medication could not be
excluded for 18 patients but was assessed as unlikely. The
total number of days of exposure to study medication
reached 16,563 days for EPs 7630 and 16,998 days for pla-
cebo resulting in an incidence of suspected adverse drug
reactions (events/day of exposure) of 0.001 and <0.001,
respectively. All other AEs were considered as “unrelated”
to study medication. According to the system organ clas-
sification, “gastrointestinal disorders” (EPs 7630: 16.2%/
placebo: 6.9%) was the most frequently reported system
organ class for which a causal relationship could not be
excluded.
Clinical laboratory parameters showed no relevant group
differences between baseline and treatment termination.
The percentage of patients with sputum present was also
comparable between both groups throughout the study (EPs
7630: 79.8% at baseline and 69.7% at week 24; placebo:
75.3% at baseline and 76.2% at week 24).
Table 1 Demographic, clinical and physiological data at baseline (ITT population, nZ 199) (number (%) or mean  standard
deviation).a
Demographic characteristics EPs 7630
(n Z 98)
Placebo
(n Z 101)
Sex
male 46 (46.9%) 42 (41.6%)
female 52 (53.1%) 59 (58.4%)
Age (years) 51.9  9.8 50.3  12.1
Height (cm) 168.6  8.7 169.4  8.2
Weight (kg) 79.5  12.9 77.7  15.1
Body mass index (kg/m2) 28.0  4.3 27.1  4.9
Number of exacerbations during the past 12 months
3 exacerbations 82 (83.7%) 90 (89.1%)
4 exacerbations 16 (16.3%) 11 (10.9%)
Smoker status
Current smoker 44 (44.9%) 42 (41.6%)
Pack year calculation 17.5 14.8
Ex-smoker 13 (13.3%) 21 (20.8%)
Pack year calculation 18.0 15.6
Never-Smoker 41 (41.8%) 38 (37.6%)
Total number of patients with comorbidities 75 (76.5%) 80 (79.2%)
Main comorbidities according to system organ classes
Cardiac disorders 10 (10.2%) 15 (14.9%)
Gastrointestinal disorders 25 (25.5%) 23 (22.8%)
Hepatobiliary disorders 27 (27.6%) 28 (27.7%)
Metabolism and nutrition disorders 14 (14.3%) 12 (11.9%)
Musculoskeletal and connective tissue disorders 18 (18.4%) 14 (13.9%)
Vascular disorders 24 (24.5%) 23 (22.8%)
Score of cough, sputum production and sternal pain 5.59  1.21 5.72  1.32
Spirometry at baseline before and after ipratropiumbromide/fenoterol
FEV1 predicted (%) before 60.92  12.04 59.76  11.87
after 63.81  13.01 62.83  12.69
FEV1 (l) before 1.95  0.56 1.93  0.52
after 2.04  0.58 2.03  0.55
FVC (l) before 2.57  0.80 2.57  0.69
after 2.66  0.79 2.67  0.73
FEV1 Z Forced Expiratory Volume during one second; FVC Z forced vital capacity.
a Statistical testing revealed no descriptively significant difference at baseline.
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This study was designed to evaluate the effect of EPs 7630
as add-on therapy to a standardised baseline-treatment in
patients with moderate to severe COPD. As it is recom-
mended that pharmacological trials in COPD should last at
least three and ideally six months in order to look at clini-
cally meaningful outcomes in COPD,27 treatment duration in
this study was 24 weeks. COPD patients with frequent ex-
acerbations in the past have a larger probability of suffering
frequent COPD exacerbations in the future.24 Therefore, in
order to allow reliable detection of a possible effect on the
time to first exacerbation and exacerbation frequency dur-
ing the study period, only patients with at least 3 exacer-
bations during the past 12 months were allowed to enter the
study. Due to the short recruitment duration of only 4
months and due to the block randomisation used in the trial,
the study participants are considered to be comparable
concerning any seasonal impact.The comparably low age of COPD patients seen in this
study is in line with results from other recently published
Ukrainian trials.28,29 This supports the results of a systemic
review and meta-analysis of studies carried out in 28 coun-
tries between 1990 and 2004 which show that the prevalence
of COPD is already higher in patients over 40 years of age.3
The results of the presented trial show statistically sig-
nificant superiority of EPs 7630 compared to placebo in the
confirmatory analysis for the primary efficacy variable “time
to first acute exacerbation”, which was significantly pro-
longed in EPs 7630-treated patients (p Z 0.005, one-sided
centre-stratified log-rank test) e especially in acute exac-
erbations which led to an extra visit by the patient (mod-
erate exacerbations, p < 0.0001). In mild exacerbations
derived from the patient’s diary on the basis of a twofold
increase in ipratropiumbromide/fenoterol consumption on
at least 5 days, this difference was not significant. This
finding is in line with the fact that ascertainment using less
specific healthcare utilisation data such as a change in
(b) moderate exacerbations
(a) moderate and mild exacerbations
(c) mild exacerbations
Figure 2 Survival function estimates. (a) Moderate and mild
exacerbations, (b) moderate exacerbations only, (c) mild ex-
acerbations only. p-values of the one-sided centre-stratified
log-rank test.
Efficacy of EPs 7630 in COPD 697regular medication is considered to be less satisfactory and
that the onset of an exacerbation could be better defined
from the date of first healthcare contact.30
Subgroup analyses of the time to first moderate exac-
erbations revealed a significant superiority of EPs 7630
compared to placebo for both genders, patients in COPD
stage II, and for every smoker status. For the subgroup ofsmokers, the time to first moderate and mild exacerbations
was significantly longer in the EPs 7630 group compared to
placebo. For COPD III patients, the survival curve of EPs
7630 was above that of placebo, but the difference did not
reach significance due to the small patient number in this
subgroup. Although cigarette smoking is still the most
commonly encountered risk factor, there is consistent evi-
dence from published studies that non-smokers may also
develop COPD due to exposure to indoor and outdoor air
pollution, workplace exposure to dust, fumes or chemicals,
passive smoking, history of repeated lower respiratory-
tract infections during childhood, history of pulmonary
tuberculosis, chronic asthma, intrauterine growth retarda-
tion, poor nourishment, and poor socioeconomic sta-
tus.4e7,31 In this study, about one third of participants were
non-smokers and the average pack-years were only 15e18.
This is consistent to the results of a review published
recently, which show that the proportion of non-smoking
COPD patients worldwide is much higher than previously
believed in both developed and developing countries,
amounting to up to 35e50% in recent studies.31 There was a
comparable but slightly higher percentage of women in
both groups. As shown by the results of the performed
subgroup analysis according to gender, this did not affect
the study outcome of this trial, although there was a larger
proportion of non-smokers among the female population.
The high percentage of non-smoking women in this study is
not surprising as, in Ukraine, about three-quarters of
women are non-smokers while a percentage of household
cooking with solid fuel of up to 75% was reported.32 Indoor
pollution from biomass cooking and heating in poorly
ventilated dwellings is an important risk factor for COPD,
especially among women in developing countries.31,33
Significant differences in favour of EPs 7630 were also
shown for secondary parameters, e.g., reduction in exac-
erbation frequency, less consumption of antibiotics,
improved quality of life, higher patient satisfaction with
treatment and less days of inability to work. COPD patients
develop significant disability during progressive disease,
and respiratory disease-specific questionnaires, such as the
SGRQ, provide sensitive measurements of disturbance in
daily life and well-being. Effects on health status are
therefore a useful outcome measure in COPD and a reduc-
tion in exacerbation frequency and less need for antibiotics
as shown in this study would be expected to result in
improved well-being.23
This also holds true for our study in which EPs 7630-
treated patients showed a consistent, statistically signifi-
cant and clinically meaningful improvement in health sta-
tus and fewer days off work. In the EPs 7630 group, the
mean number of moderate exacerbations calculated for
one year was about one exacerbation less compared to
placebo. This difference corresponds to the suggested
minimal clinically important difference (MCID) of exacer-
bation frequency in COPD.34
Looking at SGRQ score results, the placebo response rate
seen in our study might appear to be surprisingly high.
Nevertheless, a comparable placebo response rate was
seen in a 9-month, randomised, double-blind, multicenter
study comparing the effect of tiotropium and placebo in
554 patients with moderate to severe COPD: for the sub-
group of patients with comparable FEV1 values as measured
Table 2 Two-sided p-values of the log-rank test for moderate exacerbations of different subgroups, mean FEV1 predicted at
baseline before/after reversibility test and mean daily puffs of inhalative ipratropiumbromide/fenoterol (ITB/Fen) during the
study.
EPs 7630 (n Z 98) Placebo (n Z 101) p-value (log-rank
test, two-sided)
COPD II p < 0.0001
Number of patients 79 (80.6%) 78 (77.2%)
FEV1 predicted (%) at baseline
before ITB/Fen 65.5  8.1 64.8  8.1
after ITB/Fen 68.4  9.4 67.9  9.1
ITB/Fen (mean daily inhaled puffs  SD) 0.98  0.76 1.02  0.72
COPD III p Z 0.2426
Number of patients 19 (19.4%) 23 (22.8%)
FEV1 predicted (%) at baseline
before ITB/Fen 41.9  5.1 42.8  4.9
after ITB/Fen 44.8  7.7 45.6  6.1
ITB/Fen (mean daily inhaled puffs  SD) 1.98  1.18 1.91  1.15
Smokers p Z 0.0016
Number of patients
male 30 (65.2%) 25 (59.5%)
female 14 (26.9%) 17 (28.8%)
FEV1 predicted (%) at baseline
before ITB/Fen 63.4  12.2 60.7  10.3
after ITB/Fen 66.6  12.6 63.9  10.7
ITB/Fen (mean daily inhaled puffs  SD) 1.12  0.99 1.18  0.93
Ex-Smokers p Z 0.0127
Number of patients
male 8 (17.4%) 11 (26.2%)
female 5 (9.6%) 10 (17.0%)
FEV1 predicted (%) at baseline
before ITB/Fen 55.0  10.7 58.8  16.6
after ITB/Fen 57.5  11.7 62.1  16.6
ITB/Fen (mean daily inhaled puffs  SD) 2.02  1.03 1.32  1.00
Never-Smokers p Z 0.003
Number of patients
male 8 (17.4%) 6 (14.3%)
female 33 (63.5%) 32 (54.2%)
FEV1 predicted (%) at baseline
before ITB/Fen 60.1  11.8 59.3  10.6
after ITB/Fen 62.8  13.3 62.1  12.6
ITB/Fen (mean daily inhaled puffs  SD) 0.97  0.69 1.21  0.86
Male p < 0.0001
Number of patients 46 (46.5%) 42 (41.6%)
FEV1 predicted (%) at baseline
before ITB/Fen 58.5  12.9 56.3  13.3
after ITB/Fen 60.6  13.5 59.5  13.7
ITB/Fen (mean daily inhaled puffs  SD) 1.33  1.03 1.46  1.02
Female p < 0.0001
Number of patients 52 (52.5%) 59 (58.4%)
FEV1 predicted (%) at baseline
before ITB/Fen 63.0  10.9 62.2  10.2
after ITB/Fen 66.7  11.9 65.2  11.5
ITB/Fen (mean daily inhaled puffs  SD) 1.04  0.83 1.05  0.80
Values of FEV1 predicted are given as mean  SD.
698 H. Matthys et al.in our study (baseline FEV1 > 50% predicted), an improve-
ment of 7.381.44 points under placebo was reported.35
In our study, the difference in the mean decrease of the
SGRQ total score from baseline to week 24 was 5.7 pointshigher in the EPs 7630 group as compared to placebo and
therefore above the suggested MCID of 4 points for this
measure.36 When considering the fact that all patients of
our own trial received baseline-treatment for COPD
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Figure 5 Mean duration (days) of inability to work during an
exacerbation, total number of days with inability to work
during exacerbations and during the 24-week study period.
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Figure 3 Health impairment according to the St. George’s
respiratory questionnaire (SGRQ) during treatment phase (p-
value of two-sided t-test <0.01, between-group comparison
for difference to baseline).
Efficacy of EPs 7630 in COPD 699according to GOLD and that the documented intake of
concomitant medication was comparable between both
groups, the advantage as shown for EPs 7630 compared to
placebo appears to be even more impressive.
The efficacy and safety of EPs 7630 in patients suffering
from RTI e like acute bronchitis, rhinosinusitis and common
cold e with a significantly faster reduction in disease-
specific symptoms like coughing, sputum production and
dyspnoea have already been shown.16,17,37e40 Whether the
overall benefit of EPs 7630 treatment in COPD e a multi-
component disease, associated with inflammation, airway
obstruction, mucociliary dysfunction and structural
changes in the lung e is solely attributable to the anti-
microbial effects and notable immune-modulatory capa-
bilities shown for EPs 7630 and its isolated constituents in
in-vitro studies10e15 has yet to be determined. However,
the analysis showed consistently greater efficacy of EPs
7630 compared to placebo when added to basic COPD
therapy.
In conclusion, the results of this study with EPs 7630
demonstrate a statistically significant and clinically rele-
vant superiority over placebo in the add-on treatment of
patients with moderate to severe COPD, which was shown
in prolongation of time to first exacerbation and by
reducing exacerbation frequency and antibiotic use. EPs0
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Figure 4 Patient satisfaction with treatment (IMPSS). Rela-
tive frequencies of the categories at week 24 and p-value of
two-sided ManteleHaenszel c2-test.7630 presented a good long-term safety profile. Further
clinical studies are warranted to determine the therapeutic
value of this new controller drug in COPD therapy.
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